Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report report published on Saturday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Trading Down 1.4 %

Shares of NYSE ENZ opened at $0.66 on Friday. Enzo Biochem has a twelve month low of $0.63 and a twelve month high of $1.44. The stock has a 50 day moving average of $0.87 and a two-hundred day moving average of $1.04.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.

Enzo Biochem Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were given a $0.10 dividend. This represents a $0.40 annualized dividend and a yield of 60.98%. The ex-dividend date of this dividend was Friday, November 15th.

Institutional Investors Weigh In On Enzo Biochem

Several large investors have recently modified their holdings of the stock. BBR Partners LLC purchased a new position in Enzo Biochem during the third quarter worth about $112,000. Renaissance Technologies LLC increased its position in Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares during the period. XTX Topco Ltd raised its stake in shares of Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after buying an additional 13,735 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after buying an additional 11,742 shares during the period. Hedge funds and other institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.